XtalPi Holdings (2228) H2 2024 earnings summary

Executive summary

• Revenue reached RMB 266.4 million in 2024, up 53% year-over-year, with accelerated growth in the second half and strong expansion in intelligent robotics and drug discovery solutions.

• Adjusted net loss narrowed to RMB 456.8 million, down 13% year-over-year, reflecting improved operational efficiency and cost control.

• Monthly average cash burn reduced by 23% to RMB 48 million, and cash reserves exceeded RMB 3.1 billion at year-end, surpassing RMB 6 billion by March 2025.

• Customer base expanded from 75 in 2021 to over 280 in 2024, with significant international growth and high-profile partnerships.

• Commercialization of AI and robotics solutions expanded into new materials, agriculture, and traditional Chinese medicine sectors.

Financial highlights

• Revenue: RMB 266.4 million in 2024, up 53% year-over-year; second half growth accelerated to 73%.

• Adjusted net loss: RMB 456.8 million, improved 13% year-over-year.

• Monthly average cash burn: RMB 48 million, down 23% year-over-year.

• Cash and equivalents at year-end: RMB 3,123 million, rising to over RMB 6 billion by March 2025.

• R&D expenses totaled RMB 480 million, focused on personnel, cloud computing, and material technologies.

Outlook and guidance

• Plans to refine next-generation AI and robotics infrastructure, expand global footprint, and deepen collaborations with industry leaders in pharma, materials, and consumer goods.

• Sufficient working capital for approximately ten years, factoring in 2025 placings.